These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 35660546)
21. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine. Uwamino Y; Kurafuji T; Takato K; Sakai A; Tanabe A; Noguchi M; Yatabe Y; Arai T; Ohno A; Tomita Y; Shibata A; Yokota H; Yamasawa W; Namkoong H; Sato Y; Hasegawa N; Wakui M; Murata M; Vaccine; 2022 Jul; 40(32):4538-4543. PubMed ID: 35718591 [TBL] [Abstract][Full Text] [Related]
22. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
23. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457 [TBL] [Abstract][Full Text] [Related]
26. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228 [TBL] [Abstract][Full Text] [Related]
27. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related]
28. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab. Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313 [TBL] [Abstract][Full Text] [Related]
29. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab. Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373 [TBL] [Abstract][Full Text] [Related]
30. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L Front Immunol; 2022; 13():1031852. PubMed ID: 36451833 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Hayer J; Urlaub E Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594 [TBL] [Abstract][Full Text] [Related]
33. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669 [TBL] [Abstract][Full Text] [Related]
34. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
35. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project. Tylicki L; Biedunkiewicz B; Dąbrowska M; Ślizień W; Tylicki P; Polewska K; Rosenberg I; Rodak S; Dębska-Ślizień A Pol Arch Intern Med; 2021 Sep; 131(9):797-801. PubMed ID: 34351091 [TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170 [TBL] [Abstract][Full Text] [Related]